BIOGEN Q2 FY26 earnings call BIIB

Biogen is actively pursuing sustainable revenue growth, driven by its expanding growth product portfolio, which now exceeds the legacy MS portfolio. The recent acquisition of Apellis, integrating SYFOVRI and EMPAVELI, is a significant contributor to this growth. The company is also focused on a robust late-stage pipeline with multiple near-term catalysts and a rebuilt early-stage pipeline, aiming to secure long-term innovation and value creation.

The high-dose regimen of SPINRAZA has seen faster-than-expected conversion rates across all markets (Japan, Europe, U.S.), demonstrating significant efficacy benefits in a competitive market. This has led to anecdotal switchbacks from oral products and strong demand, with the high-dose regimen exceeding the original SPINRAZA launch in its first 13 weeks. This success reinforces the long-term value of the SPINRAZA franchise, supported by the upcoming salinersen.

The FDA approval of LEQEMBI IQLIK initiation, the first one-dosing Alzheimer's treatment, is a major achievement. This subcutaneous option is expected to broaden patient eligibility by simplifying administration, potentially increase patient persistence on therapy, and offer a competitive advantage. While initial demand is being tracked, the company anticipates IQLIK will evolve the Alzheimer's market by addressing patient reluctance to IV infusions and improving workflow for physicians.

The integration of Apellis, which closed on May 14, is progressing well, with SYFOVRI and EMPAVELI showing strong performance. SYFOVRI generated $162 million in revenue, up 8% YoY, with commercial injections up 13% YoY, driven by reduced free drug programs and improved HCP sentiment. EMPAVELI revenue was $46 million, up 123% YoY. The acquisition is expected to materially contribute to top-line growth and non-GAAP diluted EPS accretion by 2027, with at least $250 million in run-rate synergies by the end of 2027.

Biogen is entering a multi-year registrational cycle with 5 Phase III readouts expected within the next four quarters across SLE, CLE, AMR, and Dravet syndrome. Notably, the Phase III readouts for felzartamab in AMR and mitipiimab in CLE have been accelerated to the first half of 2027. These opportunities represent significant potential for long-term growth, with lupus alone estimated as an $8 billion market and AMR as a $2 billion addressable market.

The company has made dramatic moves to overhaul its research organization, resulting in 3 IND filings this year and plans to add 6 new programs, including Phase II proof-of-concept studies and first-in-human studies. Strategic collaborations and acquisitions, such as the pending Vatera transaction, are boosting the early-stage pipeline, laying the groundwork for products launching in the mid-2030s and building a durable innovation engine.

Biogen sees a significant unmet need in lupus, particularly in CLE where less than 5% of patients receive advanced therapy. The company's SLE trials (TOPAZ 1 and 2) are designed to address high placebo responses and patient heterogeneity, focusing on patients with skin and joint involvement. The upcoming 52-week data for litefolumab in CLE at EADV is expected to provide important insights into durability, with management confident in the potential for a differentiated treatment.

Felzartamab in Antibody-Mediated Rejection (AMR) is viewed as a potential $2 billion addressable market, with Phase III data expected in H1 2027. The Phase II data showed an 80% resolution of AMR, and there is currently no approved product for this high unmet need. The company is also pursuing microvascular inflammation (MVI), a sizable population of 6,000 patients in the U.S., with a trial already underway, believing felzartamab's mechanism of action will be impactful in both indications.